VYGR Profile
Voyager Therapeutics, Inc., a pioneering gene therapy company, is at the forefront of developing cutting-edge treatments and platform technologies aimed at addressing severe neurological disorders. The company's lead clinical candidate, VY-AADC, is currently undergoing an open-label Phase 1 clinical trial to evaluate its efficacy in treating Parkinson's disease. VY-AADC represents a promising approach to restoring dopamine production in the brain, potentially offering significant therapeutic benefits for patients with Parkinson's disease who have limited options.
In addition to VY-AADC, Voyager Therapeutics is advancing several preclinical programs targeting a range of neurodegenerative and genetic diseases. These include VY-SOD102, which is being developed for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative condition. VY-HTT01 is focused on Huntington's disease, while VY-FXN01 aims to address Friedreich's ataxia, a genetic disorder that affects coordination and muscle control. The company is also working on a Tau program designed to target tauopathies such as Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as spinal muscular atrophy.
Voyager Therapeutics has established strategic collaborations and license agreements with major pharmaceutical companies, including Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma A.G. These partnerships are integral to the research, development, and commercialization of adeno-associated virus (AAV) gene therapy products. Through these collaborations, Voyager leverages its expertise in gene therapy to accelerate the development of transformative treatments for serious neurological conditions.
Founded in 2013 and headquartered in Cambridge, Massachusetts, Voyager Therapeutics is committed to advancing its innovative gene therapy technologies and improving patient outcomes. The company's robust pipeline and strategic alliances position it as a key player in the gene therapy landscape, with the potential to make significant contributions to the treatment of complex neurological diseases.
|
